» Articles » PMID: 19917915

A Case-control Study of Smoking and Bladder Cancer Risk: Emergent Patterns over Time

Abstract

Background: Cigarette smoking is a well-established risk factor for bladder cancer. The effects of smoking duration, intensity (cigarettes per day), and total exposure (pack-years); smoking cessation; exposure to environmental tobacco smoke; and changes in the composition of tobacco and cigarette design over time on risk of bladder cancer are unclear.

Methods: We examined bladder cancer risk in relation to smoking practices based on interview data from a large, population-based case-control study conducted in Maine, New Hampshire, and Vermont from 2001 to 2004 (N = 1170 urothelial carcinoma case patients and 1413 control subjects). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression. To examine changes in smoking-induced bladder cancer risk over time, we compared odds ratios from New Hampshire residents in this study (305 case patients and 335 control subjects) with those from two case-control studies conducted in New Hampshire in 1994-1998 and in 1998-2001 (843 case patients and 1183 control subjects).

Results: Regular and current cigarette smokers had higher risks of bladder cancer than never-smokers (for regular smokers, OR = 3.0, 95% CI = 2.4 to 3.6; for current smokers, OR = 5.2, 95% CI = 4.0 to 6.6). In New Hampshire, there was a statistically significant increasing trend in smoking-related bladder cancer risk over three consecutive periods (1994-1998, 1998-2001, and 2002-2004) among former smokers (OR = 1.4, 95% CI = 1.0 to 2.0; OR = 2.0, 95% CI = 1.4 to 2.9; and OR = 2.6, 95% CI = 1.7 to 4.0, respectively) and current smokers (OR = 2.9, 95% CI = 2.0 to 4.2; OR = 4.2, 95% CI = 2.8 to 6.3; OR = 5.5, 95% CI = 3.5 to 8.9, respectively) (P for homogeneity of trends over time periods = .04). We also observed that within categories of intensity, odds ratios increased approximately linearly with increasing pack-years smoked, but the slope of the increasing trend declined with increasing intensity.

Conclusions: Smoking-related risks of bladder cancer appear to have increased in New Hampshire since the mid-1990s. Based on our modeling of pack-years and intensity, smoking fewer cigarettes over a long time appears more harmful than smoking more cigarettes over a shorter time, for equal total pack-years of cigarettes smoked.

Citing Articles

Modeling Historic Arsenic Exposures and Spatial Risk for Bladder Cancer.

Boyle J, Ward M, Koutros S, Karagas M, Schwenn M, Johnson A Stat Biosci. 2024; 16(2):377-394.

PMID: 39247147 PMC: 11378980. DOI: 10.1007/s12561-023-09404-7.


Urinary mutagenicity and bladder cancer risk in northern New England.

Wong J, Fischer A, Baris D, Beane Freeman L, Karagas M, Schwenn M Environ Mol Mutagen. 2024; 65(1-2):47-54.

PMID: 38465801 PMC: 11089907. DOI: 10.1002/em.22588.


Occupational exposure to organic solvents and risk of bladder cancer.

Xie S, Friesen M, Baris D, Schwenn M, Rothman N, Johnson A J Expo Sci Environ Epidemiol. 2024; 34(3):546-553.

PMID: 38365975 PMC: 11222140. DOI: 10.1038/s41370-024-00651-4.


Matched analysis of detailed peripheral blood and tumor immune microenvironment profiles in bladder cancer.

Chen J, Salas L, Wiencke J, Koestler D, Molinaro A, Andrew A Epigenomics. 2024; 16(1):41-56.

PMID: 38221889 PMC: 10804212. DOI: 10.2217/epi-2023-0358.


Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes.

Chen J, Salas L, Wiencke J, Koestler D, Molinaro A, Andrew A Cancer Epidemiol Biomarkers Prev. 2023; 32(10):1328-1337.

PMID: 37527159 PMC: 10543967. DOI: 10.1158/1055-9965.EPI-23-0331.


References
1.
Riedel K, Scherer G, Engl J, Hagedorn H, Tricker A . Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J Anal Toxicol. 2006; 30(3):187-95. DOI: 10.1093/jat/30.3.187. View

2.
Fortuny J, Kogevinas M, Zens M, Schned A, Andrew A, Heaney J . Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 2007; 7:13. PMC: 2018698. DOI: 10.1186/1471-2490-7-13. View

3.
Van Hemelrijck M, Michaud D, Connolly G, Kabir Z . Secondhand smoking, 4-aminobiphenyl, and bladder cancer: two meta-analyses. Cancer Epidemiol Biomarkers Prev. 2009; 18(4):1312-20. DOI: 10.1158/1055-9965.EPI-08-0613. View

4.
Wynder E, Hoffmann D . Re: Cigarette smoking and the histopathology of lung cancer. J Natl Cancer Inst. 1998; 90(19):1486-8. DOI: 10.1093/jnci/90.19.1486. View

5.
Masuda Y, Hoffmann D . Quantitative determination of 1-naphthylamine and 2-naphthylamine in cigarette smoke. Anal Chem. 1969; 41(4):650-2. DOI: 10.1021/ac60273a017. View